CDC National VZV Laboratory
The National VZV Laboratory operates within the National Center for Immunizations and Respiratory Diseases, Division of Viral and Diseases. This laboratory supports surveillance efforts toward monitoring the impact of varicella vaccination in the U.S. population, outbreak investigations, and confirmation of disease, vaccine adverse events, VZV breakthrough infections with wild-type virus, and disease susceptibility.
The National VZV Laboratory can provide several types of VZV-specific testing free-of-charge to state and local public health departments who require confirmatory evidence for VZV infection or confirmation of atypical herpes zoster cases, and to physicians and scientists participating in various epidemiologic and laboratory-based studies.
Specimens may be submitted for suspected vaccine-related adverse events, including herpes zoster in a person who received varicella or zoster vaccine, a varicella-like rash with more than 50 lesions 7-42 days after varicella vaccination, any serious adverse event (pneumonia, ataxia, encephalitis) occurring after vaccination, and suspected secondary transmission.
For more information on varicella zoster virus specimen collection, storage, and handling, please contact:
Centers for Disease Control and Prevention
National VZV Laboratory
1600 Clifton Road, NE
Mailstop G-18 (Building 18, Room 6-134—for FedEx shipments)
Atlanta, GA 30333
Phone: (404) 639-3667
Images and logos on this website which are trademarked/copyrighted or used with permission of the trademark/copyright or logo holder are not in the public domain. These images and logos have been licensed for or used with permission in the materials provided on this website. The materials in the form presented on this website may be used without seeking further permission. Any other use of trademarked/copyrighted images or logos requires permission from the trademark/copyright holder...more
This graphic notice means that you are leaving an HHS Web site. For more information, please see the Exit Notification and Disclaimer policy.